It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Looking for ways to make immediate money? Discover effective strategies that can help you earn fast and address your financial needs.
16,413 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Borrowers with a 600 credit score face tighter lending, but flexible programs from a handful of lenders are expanding...
The 2026 IPO boom is broadening beyond AI megadeals as mid-cap and overlooked sectors attract new capital. A busy sec...
A single Vanguard ETF has quietly led the charge over the past ten years by keeping costs ultra-low and sticking to t...
GE Aerospace delivered strong results in 2026, but the broader XLI index outpaced the stock through July. Here's what...
Cybersecurity shares jumped after inflation data cooled, lifting risk sentiment. CrowdStrike climbs 11% and Palo Alto...
Morgan Stanley reveals a sharper cost curve for AI data centers, suggesting only a few players can fund the next wave...
A timely look at how independent journalism survives in 2026, focusing on Amy Goodman and the economics of free‑press...
A high-value delivery went missing from a FedEx facility, valued at nearly $241k. The coins later showed up in pawn s...
Palantir stock slipped from its peak, triggering questions about value, risk, and timing for late 2026. This guide br...
Rising gray divorces are reshaping retirement planning. Some ex-spouses may claim up to 50% of the other’s Social Sec...
A three-move tactic lets owners of appreciated assets defer capital gains by borrowing against holdings, then pass th...